OncoSil MEDICAL Ltd

New Technology To Provide Safer Radiotherapy Treatments

OncoSil Medical

28th November 2014

ASX: OSL

Shareholder Update
AGM 2014

Important Notice

The purpose of the presentation is to provide an update of the business of OncoSil Medical Ltd (ASX:OSL). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by OncoSil Medical Ltd and should not be relied upon as an independent source of information. Please contact OncoSil Medical Ltd and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. None of OncoSil Medical Ltd, or any of its affiliates or associated companies(or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfilment of any forward looking statement or any outcomes expressed or implied in any forward looking statements. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside OncoSil Medical Ltd's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and OncoSil Medical Ltd's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events. This presentation should not be relied on as a recommendation or forecast by OncoSil Medical Ltd. Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

OncoSil™ - Potential treatment for Pancreatic Cancer

Next Generation Radiotherapy

- OncoSil Medical has an **implantable nuclear medicine (radiotherapy) device** that is commencing a pivotal study in pancreatic cancer.
- **Localised radiation therapy** is inherently safe, effective and well tolerated and matches well with the features of pancreatic cancer.
- There are highly **commercially successful precedents** for radiation therapy in:
  - Prostate cancer - Xofigo, Bayer ($2.4bn acquisition of Algeta) – metastatic to bone
  - Liver cancer – SIR-Sphere, Sirtex
  - Non Hodgkin's Lymphoma – Zevalin, Spectrum Pharmaceuticals – tagerted antibody

Localised radiotherapy is a potential new approach for pancreatic cancer patients.

OncoSil™

OncoSil MEDICAL Ltd
New Technology To Provide Safer Radiotherapy Treatments

Radiation therapy delivered to the cancer site

- **Pure beta radiation source (P32)** to avoid systemic side effects
- **Localised radiation therapy** using “sticky” microparticles
- **Carrier particles are inert silicon**
- **Particles are suspended in fluid** to allow direct injection into the tumour
- **Single Injection** under anesthesia takes 30 minutes
- **Local radiation in the tumour lasts around 3 months**

How OncoSil™ Works

OncoSil™ is suspended in a shielded syringe in the operating theatre where a physician will make the injection of the device into the pancreatic tumour.





The physician guides an endoscope down the oesophagus, through the stomach and into the first part of the small intestine. Ultrasound is used to image the tumour in the pancreas, then extends a needle from the end of the scope into the pancreas and into the middle of the tumour.



The physician then injects the OncoSil™ suspended in fluid directly into the tumour.

OncoSil™ Benefits

- Localised treatment reduces serious side effects associated with standard radiotherapy
- Classified as a device therefore shorter time to market than traditional drug development
- Synergistic effect with current chemotherapy regime as gemcitabine ‘sensitise’ cells to radiation therapy

Unmet Medical need



Unmet Medical need

- Current treatment $60,000/patient
- 280,000+ pancreatic cancer incidence yearly world wide (1)
- Approximately 45,000 new patients diagnosed with pancreatic cancer in the US each year
- Poor prognosis -Median survival ~8 months and 5 year survival less than 7%

Clinical data to date

OncoSil MEDICAL Ltd
New Technology To Provide Safer Radiotherapy Treatments

Clinical Trial Results

- 17 inoperable pancreatic cancer patients in single arm study
- Significant anti-cancer activity – disease control rate of 82% : 4 Partial Responses, 10 Stable disease and 3 Progressive Disease
- Average reduction in pain of 35% - with a maximum reduction of 69% between weeks 8 and 11 following implant
- Median progression free survival was 121 days
- Median overall survival was 309 days or 10+ months (compared with a typical 5.7 months with gemcitabine alone)

Global Regulatory Strategy

Device Registration Plan for Key Pharmaceutical Markets



OncoSil's global registration strategy is with CE (Conformité Européenne) mark, and with the United States FDA (Food and Drug Administration. IDE: Investigational Device Exemption.

Pivotal Trial

Endpoints

Primary:

- Overall survival (time from randomization to death)

Secondary:

- Progression free survival (time to clinical or radiological confirmed progression)
- Quality of Life (EORTC Scale)
- Pain (Brief Pain Index, point of time and 24 hours)

Challenges

- No prior state-of-the art studies to reference
- Investigator buy-in
- Global Study design
- Supply logistics and global co-ordination

Pivotal Trial – Why the Delay

OncoSil MEDICAL Ltd
New Technology To Provide Safer Radiotherapy Treatments

1. We announced that we had approval to begin a pivotal trial in Australia

2. Protocol being amended to meet US and EU regulatory recommendations

3. Trial design is being modified to increase the statistical powering

4. Manufacturing and logistical process is being finalised to comply with local importation requirements

OncoSil™ Manufacturing

Starting material

- Mix Silicon and Phosphorus at 1480°C
- Atomise with water to create Si-P micro particles

Create 32P Micro particles

- Grade particles to 30 microns
- Etch with acid to create porosity
- Place in a high neutron reactor

Dosing

- Package and ship in lead containers
- Pharmacist reconstitutes OncoSil™
- Patient is dosed

Patents, Trademark & Know How

- Multiple granted patents in US, EU, Japan and elsewhere for the therapeutic product and for the manufacturing method (2022 - 2024)
- Trademark protection granted for OncoSil™ in Australia, New Zealand, UK, EU, USA, Japan and Singapore

Know-How, Expertise and Trade Secrets

- Brachytherapy clinical trial management
- Manufacturing and distribution logistics

Board Management Slide

Executive Chairman:	Dr. Roger Aston
Non-Executive Director:	Mr. Lawrence Gozlan
Non-Executive Director:	Mr. Martin Rogers
Managing Director and CEO:	Mr. Daniel Kenny
Financial Controller & Company Secretary:	Mr. Peter Casey
Head of EU Operations:	Dr. Drew Ferguson
Chief Scientific Officer:	Dr. Peter Knox
VP Clinical Research:	Ms. Natalie Ruffles